The efficacy of fluticasone furoate administered in the morning or evening is comparable in patients with persistent asthma
详细信息 查看全文
- 作者：R.D. Kempsforda ; Rodger.D.Kempsford@gsk.com" class="auth_mail" title="E-mail the corresponding author ; J. Balb ; joanne.x.bal@gsk.com" class="auth_mail" title="E-mail the corresponding author ; A. Bainesa ; Amanda.J.Baines@gsk.com" class="auth_mail" title="E-mail the corresponding author ; J. Renauxb ; jessica.f.renaux@gsk.com" class="auth_mail" title="E-mail the corresponding author ; R. Ravindranathc ; r.2.ramiya@gsk.com" class="auth_mail" title="E-mail the corresponding author ; P.S. Thomasd ; Paul.Thomas@unsw.edu.au" class="auth_mail" title="E-mail the corresponding author
- 关键词：Asthma ; Inhaled corticosteroid ; Fluticasone furoate ; Efficacy ; Morning dosing ; Evening dosing
- 刊名：Respiratory Medicine
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：112
- 期：Complete
- 页码：18-24
- 全文大小：575 K
文摘
- •
Timing of once-daily fluticasone furoate (FF) was studied for efficacy in asthma.
- •
Morning (AM) or evening (PM) FF100 μg, and placebo were compared.
- •
Forced expiratory volume in 1 s (FEV1) was measured on Day 14.
- •
AM and PM dosing were comparable for 24-h and pre-treatment FEV1.
- •
There was also no difference in adverse event incidence between AM and PM dosing.